More Videos
SPECIAL REPORT
MOST SHARED
- Garlic Price Rises Surpass Gold, Stocks in China
- New-Home Sales Jump 6.2% To Highest Level in Over Year
- S&P Stocks Trading at New 52-Week Highs
- US Plans to Reduce Emissions By 17% Within Next Ten Years
- Judge Erases Couple's $525,000 Mortgage Payment
- The Executive Job Search
- Where Do Pardoned Turkeys Go?
- Salvation Army's Kettles Now Credit Card-Ready
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- Activision Prepares to Double Dip on ‘Modern Warfare 2’
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- AIG, Ex-CEO Greenberg Reach Pact to Settle Disputes
- Bank of America CEO Search May Extend Into 2010
- 'Cancer of Fraud' Permeates Health Care System: Critics
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- Judge Erases Couple's $525,000 Mortgage Payment
- For Many in US, It Will Be a Scaled-Down Holiday Season
- Where Do Pardoned Turkeys Go?
- Jobless Claims Below 500,000, Durable Orders Slip
- Activision Prepares to Double Dip on ‘Modern Warfare 2’
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
The current issue (February 18, 2008) of New York Magazine has a story that it teases on the cover above the masthead, "No Smoking Wonder Drug." Below it, in drug-label fine print the sub-head is: "Makes quitter talk to potted plants."
And then in the centerfold, there are two blue-tinged, artsy, blurry, smoke-filled pictures--presumably of the author--with the headline, "This Is My Brain on Chantix." You can read it here.
It's a first-person account from a New Yorker who went on the drug and claims he started having hallucinations, vivid dreams, bouts of paranoia, going on a rampage, and fleeting thoughts about killing himself. If it's all true, this guy went on quite a trip. And it's prominently featured in a magazine based in and about Pfizer's [PFE
Loading...
()
] hometown (the company's headquartered in midtown Manhattan).
I don't have the subscription numbers, but anecdotally I can safely say that New York is a mag with pretty broad readership in the New York area and is delivered to homes and sold on newsstands across the country. It's also circulating in the blogosphere. So, this is the kind of thing analysts might refer to as "headline risk."
I had recently blogged that one analyst noticed Chantix prescriptions had bounced back around the beginning of this year, but said it was too soon to tell if it was a new year's resolution effect and/or a shedding of recent safety concerns.
But that was before Pfizer changed the label to reflect neuropsychiatric side effects and the Food and Drug Administration put out a Public Health Advisory on the drug. I suspect we'll get a detailed update from Pfizer at its analyst meeting on March 5th.
PFE shares are benefiting from the market and sector rally today. But they remain rangebound in the low to sometimes mid-20s. A price investors who have a long position in the stock wish were a hallucination.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes